Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery

Official title

Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose

Overview

The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.

Detailed description

Potential subjects will consist of parturients who present for scheduled elective cesarean deliveries. Patients will be recruited and consented for the study pre-operatively and if they display Grade 3 or 4 shivering at the time of delivery then they will be enrolled in the study. Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect - cessation of shivering within 5 minutes of medication administration. An anesthesia physician not involved in patient care or assessment will prepare the dexmedetomidine for intravenous use. Anesthesia will be initiated with spinal anesthesia with our institution's typical dosing of 1.6 mL 0.75% bupivacaine with dextrose, 15 mcg fentanyl, and 150 mcg morphine.

Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan. Members of the anesthesia team caring for women in the study will be educated on the grading scales.

* Grade 0: no shivering; * Grade 1: one or more of the following: piloerection, peripheral vasoconstriction, peripheral cyanosis, but without visible muscle activity; Grade 2: visible muscle activity confined to one muscle group; * Grade 3: visible muscle activity in more than one muscle group; * Grade 4: gross muscle activity involving the whole body

Interventions

• Drug Dexmedetomidine
  Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect

Primary outcome measures

• Shivering will be graded using a five-point scale as outlined by Crossley and Mahajan [Time frame: 5 minutes after administration of the drug]

Secondary outcome measures (2)

• Maternal Heart Rate [Time frame: During intraoperative course]
• Doses of dexmedetomidine [Time frame: During intraoperative course]

Eligibility criteria

Inclusion criteria

• Women presenting for planned cesarean delivery.
• American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.
• Singleton gestation in the 3rd trimester (28-42 weeks gestation).
• Spinal anesthesia technique Women presenting for planned cesarean delivery.
• American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.
• Singleton gestation in the 3rd trimester (28-42 weeks gestation).
• Spinal anesthesia technique.

Exclusion criteria

• Any contraindication to spinal anesthesia technique.
• Allergy or intolerance to dexmedetomidine or clonidine.
• Oral temperature < 36° Celsius prior to procedure.
• Unable to give personal consent.
• PPROM or concern for infection (e.g., chorioamnionitis).
• Conversion to General Anesthesia prior to randomization.
• Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered prior to randomization.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT04730609 · 20-004712

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗